1 / 25

A.Dravid 1 ,A.Sadre 2 ,S.Dhande 1 , A.Borkar 1 ,M.Kulkarni 1 ,M.Dravid 3

Tenofovir nephrotoxicity in resource limited setting of Western India : Higher rate of renal function decline, acute kidney injury and progression to chronic kidney disease compared to Western data. A.Dravid 1 ,A.Sadre 2 ,S.Dhande 1 , A.Borkar 1 ,M.Kulkarni 1 ,M.Dravid 3

wes
Download Presentation

A.Dravid 1 ,A.Sadre 2 ,S.Dhande 1 , A.Borkar 1 ,M.Kulkarni 1 ,M.Dravid 3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tenofovir nephrotoxicity in resource limited setting of Western India : Higher rate of renal function decline, acute kidney injury and progression to chronic kidney disease compared to Western data A.Dravid1,A.Sadre2,S.Dhande1, A.Borkar1,M.Kulkarni1,M.Dravid3 1Ruby hall clinic, Department of HIV Medicine, Pune, India 2 Ruby hall clinic, Department of Nephrology, Pune, India 3 Infectious disease clinic, Department of HIV Medicine, Dhule, India

  2. Introduction • India has the second highest population of HIV positive patients in the world which stands at 2.5 million out of which 600,000 patients are on antiretroviral therapy. • Tenofovir based antiretroviral therapy is increasingly used for treatment naïve and treatment experienced patients in India over the last 5 years as per recommendation by national guidelines • It has coincided with availability of generic fixed dose combinations of Tenofovir/emtricitabine(TE), Tenofovir/Emtricitabine/Efavirenz(TEE) and Tenofovir/Lamivudine/Efavirenz(TLE) • Tenofovir nephrotoxicity is characterized by proximal tubular cell dysfunction that may be associated with Fanconi’s syndrome, acute kidney injury or progression to chronic kidney disease. • Tenofovir nephrotoxicity develops in 1-2% patients

  3. Introduction • Majority of the data on Tenofovir nephrotoxicity comes from either randomized controlled trials or from observational studies conducted in Western,resource rich settings. • Clinical trials have strict inclusion criteria and tend to exclude patients with comorbidities which hampers their generalisability to real world settings. • Data from resource limited settings like India is sparse and is plagued by missing data, limited covariates for analysis, high incidence of lost to follow up and short follow up.

  4. Objective • Primary objective of this study was to determine annual decline in estimated glomerular filtration rate(eGFR) by MDRD equation in patients taking Tenofovir based ART and comparing it with patients on Tenofovir sparing regimens • Secondary objective was to determine incidence of acute kidney injury(AKI) in Tenofovir exposed population which led to Tenofovir withdrawal. • Recovery of renal function on Tenofovir cessation was studied and proportion of patients who progress to Stage 3-5 Chronic kidney disease despite Tenofovir withdrawal was estimated.

  5. Methods • The study was carried out at Ruby Hall Clinic,Pune which is a tertiary centre for HIV/AIDS clinical care in Western India. • Electronic medical records of patients are stored in a central database from which demographic, clinical and laboratory data of all patients was extracted. • Patients who were initiated on or switched to Tenofovir based antiretroviral therapy from 1st March 2009 to 1st March 2013 were included in this retrospective observational cohort study. • Patients having atleast 1 follow up serum creatinine and creatinine clearance values were included. • Patients already on Tenofovir based ART prior to 2009 were also included provided they had regular baseline and follow up data available. • Patients started on Tenofovir sparing regimens (i.e. Zidovudine and Stavudine based regimens) during the said period were taken as control population

  6. Methods • Age,Sex,CD4 count, HBsAg status, serum creatinine, Baseline WHO stage 3-4 infection, Use of concomitant antiretroviral drugs along with Tenofovir( Non nucleoside reverse transcriptase inhibitors (NNRTI) versus protease inhibitors (PI) were the demographic variables studied. • Serum creatinine was measured at baseline and 6 monthly follow up by Von Jaffe method. • Glomerular filtration rate (eGFR) was measured at baseline and at every 6 monthly follow up by Cockcroft Gault (CG) formula and Modification of diet in renal disease(MDRD) equation. • Total duration of exposure to Tenofovir in months was calculated for each patient.

  7. Methods • Tenofovir was initiated in patients with Creatinine Clearance (Cr Cl) > 50 ml/min. • Patients started on Tenofovir at baseline Cr Cl < 50 ml/min were excluded. • Patients having missing baseline and follow up serum creatinine values were also excluded • Annual decline in GFR was calculated by CG formula and MDRD equation for Tenofovir containing and Tenofovir sparing regimens. • Acute Kidney Injury was defined as Serum creatinine > 2 mg/dl, Cr Cl decrease to < 50 ml/min or GFR decrease > 50% of baseline (Rifle criteria 2002). • Patients with GFR value < 60 ml/min(MDRD equation), 6 months after Tenofovir discontinuation were classified as having Chronic kidney disease (CKD).  • Presence of co morbidities which increase incidence of renal toxicity like diabetes mellitus, hypertension, use of concomitant nephrotoxic drugs, obstructive uropathy and urinary tract infecton were recorded. • Angiotensin converting enzyme inhibitors(ACEI), Non steroidal anti-inflammatory drugs(NSAID’s), Amino glycosides and Amphotericin B were the nephrotoxic drugs studied. • Obstructive uropathy included conditions like renal calculus disease, urethral stricture and benign prostatic hypertrophy.

  8. Methods • Entire data was analysed by the SPSS software(STATA) version 18 • One way Anova test was used to compare GFR decline amongst subgroups of patients • Multivariate logistic regression analysis was applied to the dataset to identify factors significantly associated with increasing risk of acute kidney injury in Tenofovir exposed patients

  9. Results

  10. Baseline characteristics

  11. Results (TDF exposed cohort) • Mean weight of cohort was 55.5 kg with 286/743 (38.5 %) patients having weight <= 50 kg • 437/743(58.81 %) patients had baseline CD4 count <= 200 cells/mm3 and 258/743 (34.72)% had baseline CD4 count <= 100 cells/mm3 • 30/743 (4 %) were HBsAg positive • 588/743 (79%) patients were exposed to Tenofovir with Non nucleoside reverse transcriptase inhibitors (NNRTI) and 155/743(21 %) to Tenofovir with Protease inhibitors (PI). • Mean duration of follow up was 21 months with 553/743(74.42%) patients having follow-up >=12 months. . • 214/743 (28.8%) patients had baseline creatinine clearance (CG formula) between 50-70 ml/min • 266/743(35.8 %) patients had baseline GFR (MDRD equation) between 60-90 ml/min while 22/743(2.2%) had baseline GFR between 30-60 ml/min

  12. Baseline GFR values

  13. TDF containing antiretroviral regimens

  14. eGFR decline on follow up for entire cohort

  15. eGFR decline on follow up (TDF + NNRTI vs TDF + PI)

  16. Follow up GFR decline • Mean decline in GFR in Tenofovir exposed cohort (MDRD Equation) : 5.29 ml/min/year • Mean decline in GFR in patients exposed to TDF + NNRTI only : 4.18 ml/min/year • Mean decline in GFR in patients exposed to TDF + PI only : 9.19 ml/min/year • Mean decline in GFR in patients exposed to Tenofovir sparing regimens : 1.3 ml/min/year

  17. GFR decline in presence of risk factors known to increase Tenofovir renal toxicity

  18. Tenofovir and Acute kidney injury • Number of patients who developed AKI : 36/743 (4.8%) • Time to developing AKI • < 6 months : 16 • 6 – 12 months : 5 • 12 -24 months : 8 • > 24 months : 7 • Median time to developing AKI : 8.5 months. • Number of patients requiring haemodialysis : 3/36 (8.33 %) • Number of patients who died : 4/36 (11.11 %)

  19. Analysis of risk factors which increase risk of AKI in Tenofovir exposed population by multiple logistic regression

  20. Recovery of renal function post Tenofovir withdrawal and progression to grade 3-5 chronic kidney disease • Out of 36 patients who developed AKI, 18 patients completed 6 months of follow up post Tenofovir cessation. • 4/36 patients died,2/36 were lost to follow up and 1 patient had to take Tenofovir alternate day for his Hepatitis B coinfection. • Only 1 patient had Serum creatinine >2 mg/dl, 6 months after Tenofovir withdrawal. • None of the patients have required long term renal replacement therapy as of now.

  21. Renal function recovery on TDF cessation

  22. Baseline Vs F/u GFR values

  23. Discussion • Renal function decline in patients on Tenofovir based ART was much higher than patients taking Tenofovir sparing ART (mean 5.29 ml/min/year vs 1.3 ml/min/year) • Renal function decline was higher in patients taking Tenofovir with PI’s than in patients taking Tenofovir with NNRTI (9.19 ml/min/year vs 4.14 ml/min/year). • Normal age related GFR decline in HIV negative population is 1 ml/min/year. • So in effect, eGFR decline seen in patients taking Tenofovir based ART in our cohort is similar to that seen in patients suffering from diabetic nephropathy. • The decline seems to be progressive over a period of 3 years.

  24. Discussion and conclusions • We also found higher incidence of acute kidney injury amongst our Tenofovir exposed population compared to that seen in Western resource rich settings (4.8% vs 1 %) • This could be attributable to lower baseline creatinine clearance, lower eGFR, lower baseline CD4 count and higher incidence of co-morbidities in our cohort. • Recovery of eGFR after withdrawal of Tenofovir is incomplete in significant proportion of patients in our cohort. These patients are at risk of progression to stage 3-5 Chronic kidney disease. • Finally, management of Tenofovir nephrotoxicity in resource limited settings like India is tough due to limited access to routine laboratory monitoring, renal replacement therapy and alternate antiretroviral drugs like Abacavir.

  25. CONCLUSIONS Drawbacks of our study : • Retrospective observational cohort design • CKD EPI equation and AKIN criteria could not be applied to our dataset • Routine urine examination data was not available at baseline and follow up for all the patients. It could have helped us to identify nephrotoxicity earlier. • Although we tried to identify all factors which increase risk of renal toxicity by Tenofovir, there could be unknown confounding factor which could have been missed.

More Related